Advertisement
YOU ARE HERE: LAT HomeCollectionsSimulations Plus Inc
IN THE NEWS

Simulations Plus Inc

FEATURED ARTICLES
CALIFORNIA | LOCAL
July 13, 1999
Simulations Plus Inc., Lancaster, a pharmaceutical software development company, announced that its securities have been delisted from the Nasdaq SmallCap Market. Its common stock will now be quoted and traded on the Over the Counter Bulletin Board under the symbol SIMU. Nasdaq had granted the company a temporary exception from the net tangible asset requirement in May. That exception expired July 1, and Nasdaq delisted the company's securities July 2.
ARTICLES BY DATE
CALIFORNIA | LOCAL
January 11, 2000
Simulations Plus Inc. of Lancaster reported a net loss of $42,958 for the first quarter of fiscal 2000, ended Nov. 30, compared with a net loss of $73,833 for the first quarter of 1999. Revenues declined slightly to $813,916 compared with $881,286 the year before. The company develops drug discovery and development simulation software for the pharmaceutical industry.
Advertisement
CALIFORNIA | LOCAL
January 11, 2000
Simulations Plus Inc. of Lancaster reported a net loss of $42,958 for the first quarter of fiscal 2000, ended Nov. 30, compared with a net loss of $73,833 for the first quarter of 1999. Revenues declined slightly to $813,916 compared with $881,286 the year before. The company develops drug discovery and development simulation software for the pharmaceutical industry.
CALIFORNIA | LOCAL
July 13, 1999
Simulations Plus Inc., Lancaster, a pharmaceutical software development company, announced that its securities have been delisted from the Nasdaq SmallCap Market. Its common stock will now be quoted and traded on the Over the Counter Bulletin Board under the symbol SIMU. Nasdaq had granted the company a temporary exception from the net tangible asset requirement in May. That exception expired July 1, and Nasdaq delisted the company's securities July 2.
CALIFORNIA | LOCAL
February 2, 1999
Simulations Plus Inc., a Lancaster-based developer of drug development simulation software for the pharmaceutical industry, has released Version 1.1.1 of its GastroPlus simulation software, used to predict the absorption of drugs by the human digestive system. GastroPlus is currently licensed to eight pharmaceutical companies. The company has two other businesses, Words+ and FutureLab, which are based on its software technologies. The company trades on the NASDAQ under the symbol SIMU.
BUSINESS
June 20, 1997
West Hollywood-based Bank of Los Angeles has agreed to merge with Culver City-based Culver National Bank for undisclosed terms, pending shareholder and regulatory approval. . . . Santa Clara-based Bay Networks Inc. has agreed to buy closely held Mountain View computer network technology company Rapid City Communications for $155 million in stock. . . . Palmdale-based computer simulation software maker Simulations Plus Inc. said it has commenced an initial public offering of 1.
CALIFORNIA | LOCAL
February 16, 1999
Simulations Plus Inc. has formed a joint venture with Absorption Systems LP of Exton, Pa. Lancaster-based Simulations Plus (SIMU on Nasdaq) is a developer of drug simulation software for the pharmaceutical industry. Absorption Systems is a research facility. Under the joint venture agreement, they will work together on computer programs to test new drugs for the way human bodies absorb, metabolize and eliminate compounds after they are swallowed.
BUSINESS
April 8, 2002 | DAVID COLKER, TIMES STAFF WRITER
Physicist Stephen Hawking owes his voice to Words-Plus, a Lancaster company that makes communication devices for the disabled. Lou Gehrig's disease long ago robbed him of speech, but the use of a highly sensitive pressure switch hooked into a specially designed word processor has allowed Hawking not only to write his best-selling "A Brief History of Time" but also to send e-mail, lecture and hold conversations often spiced with his sarcastic humor.
CALIFORNIA | LOCAL
February 2, 1999
Simulations Plus Inc., a Lancaster-based developer of drug development simulation software for the pharmaceutical industry, has released Version 1.1.1 of its GastroPlus simulation software, used to predict the absorption of drugs by the human digestive system. GastroPlus is currently licensed to eight pharmaceutical companies. The company has two other businesses, Words+ and FutureLab, which are based on its software technologies. The company trades on the NASDAQ under the symbol SIMU.
Los Angeles Times Articles
|